Genmab A/S (NASDAQ:GMAB) Shares Gap Up – What’s Next?

Genmab A/S (NASDAQ:GMAB) gapped up before the market opened on Wednesday . The stock had previously closed at $19.06, but opened at $19.73. Genmab A/S shares last traded at $19.76, with a volume of 304,550 shares traded.

Analysts Set New Price Targets

Several brokerages have issued reports on GMAB. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Price Performance

The business’s 50 day simple moving average is $20.91 and its 200-day simple moving average is $21.97. The stock has a market capitalization of $13.33 billion, a P/E ratio of 11.57, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the period. Barclays PLC increased its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC raised its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.